MET and neoplasm: Amivantamab binds to the extracellular domains of EGFR and cMet and blocks the binding of the ligand EGF to EGFR and the binding of the ligand HGF to its receptor cMet; it also induces degradation of both receptors in vivo, extending its effects to Ligand-independent receptor-driven diseases are included (99), and can bind to immune effector cells through ADCC to eliminate antigen-expressing tumor cells (100).